and priority review for generic complex drug products. Sec. 312. Increasing pharmaceutical options to treat an unmet medical need. Sec. 313. Preemption of State barriers to the substitution of biosimilar products. Subtitle C—Limiting Exclusivity Periods Delaying Competition Sec. 321. Limiting exclusivity periods for drugs treating rare diseases and conditions. Sec. 322. Limiting exclusivity for biosimilar products. Subtitle D—Congressional Review of Agency Rulemaking Sec. 331. Congressional review of the Food and Drug Administration rulemaking. Sec. 332. Government Accountability Office study of rules. Subtitle E—Medicare Prescription Drug Competition Sec. 341. Medicare drug coverage. Sec. 342. PBM transparency and elimination of DIR fees. Sec. 343. Sunset of limit on maximum rebate amount for single source drugs and innovator multiple source drugs. Sec. 344. Regulation of manufacturer-sponsored copay contributions. Sec. 345. Data reporting to improve the transparency regarding how 340 B hospital covered entities provide care for patients. Sec. 346. Requiring 340 B drug discount program reports by DSH hospital covered entities on low-income utilization rate of outpatient hospital services. Title IV—Provider Competition Sec. 401. Hospital consolidation. Sec. 402. Price transparency. Sec. 403. Repealing shared savings incentives from Medicare shared savings program. Sec. 404. Repeal of health care reform provisions limiting Medicare exception to the prohibition on certain physician referrals for hospitals. Sec. 405. Advisory group on reducing burden of hospital administrative requirements. Sec. 406. Authority of Federal Trade Commission over certain tax-exempt organizations. Title V—Digital Health Care Sec. 501. Access of individuals to protected health information. Sec. 502. Expansion of coverage of telehealth services. Sec. 503. STARK and AKS exemptions. Sec. 504. STARK technical penalty. I Private-Sector Health Insurance Reforms A Commercial Health Insurance Provisions 101. Invisible high risk pool reinsurance